Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): A review
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is a highly pathogenic respiratory virus with mechanisms that may be driven by innate immune responses. Despite the effort of scientific studies related to this virus, Middle East Respiratory Syndrome (MERS) is still a public health concern. ME...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
Elsevier,
2018-01-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_a42d904d05fd4009a80291f32c67c20f | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Sabeena Mustafa |e author |
| 700 | 1 | 0 | |a Hanan Balkhy |e author |
| 700 | 1 | 0 | |a Musa N. Gabere |e author |
| 245 | 0 | 0 | |a Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): A review |
| 260 | |b Elsevier, |c 2018-01-01T00:00:00Z. | ||
| 500 | |a 1876-0341 | ||
| 500 | |a 10.1016/j.jiph.2017.08.009 | ||
| 520 | |a Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is a highly pathogenic respiratory virus with mechanisms that may be driven by innate immune responses. Despite the effort of scientific studies related to this virus, Middle East Respiratory Syndrome (MERS) is still a public health concern. MERS-CoV infection has a high mortality rate, and to date, no therapeutic or vaccine has been discovered, that is effective in treating or preventing the disease. In this review, we summarize our understanding of the molecular and biological events of compounds acting as MERS-CoV inhibitors, the outcomes of existing therapeutic options and the various drugs undergoing clinical trials. Currently, several therapeutic options have been employed, such as convalescent plasma (CP), intravenous immunoglobulin (IVIG), monoclonal antibodies and repurposing of existing clinically approved drugs. However, these therapeutic options have drawbacks, thus the need for an alternative approach. The requirement for effective therapeutic treatment has brought the necessity for additional MERS treatments. We suggest that antimicrobial peptides (AMPs) may be used as alternative therapeutic agents against MERS-CoV infection. In addition, we propose the feasibility of developing effective agents by repurposing the existing and clinically approved anti-coronavirus and anti-viral peptide drugs. Keywords: MERS-CoV, Ribavirin, Interferon, Peptide therapeutics, Convalescent plasma, Intravenous immunoglobin, Antimicrobial peptides | ||
| 546 | |a EN | ||
| 690 | |a Infectious and parasitic diseases | ||
| 690 | |a RC109-216 | ||
| 690 | |a Public aspects of medicine | ||
| 690 | |a RA1-1270 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Journal of Infection and Public Health, Vol 11, Iss 1, Pp 9-17 (2018) | |
| 787 | 0 | |n http://www.sciencedirect.com/science/article/pii/S1876034117302125 | |
| 787 | 0 | |n https://doaj.org/toc/1876-0341 | |
| 856 | 4 | 1 | |u https://doaj.org/article/a42d904d05fd4009a80291f32c67c20f |z Connect to this object online. |